Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmet Dogan

Showing results (311-320 of 371) with videos related to

Pageof 38
Sort By:
Blood Cancer Journal|February 11, 2022
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphomaFushen Sha, Michelle Okwali, Anna Alperovich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2024
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated AnalysisEric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, et al.
The Journal of Clinical Investigation|September 8, 2020
Germ cell tumors and associated hematologic malignancies evolve from a common shared precursorJustin Taylor, Mark Ta Donoghue, Caleb Ho, et al.
Cancer Discovery|July 10, 2019
Altered Nuclear Export Signal Recognition as a Driver of OncogenesisJustin Taylor, Maria Sendino, Alexander N Gorelick, et al.
Nature Cancer|February 11, 2021
The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencingSara Parsa, Ana Ortega-Molina, Hsia-Yuan Ying, et al.
Cancer Discovery|January 10, 2020
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in LymphomaPatrizia Mondello, Saber Tadros, Matt Teater, et al.
The Lancet. Haematology|May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.
Science Translational Medicine|June 11, 2025
DeepHeme, a high-performance, generalizable deep ensemble for bone marrow morphometry and hematologic diagnosisShenghuan Sun, Zhanghan Yin, Jacob G Van Cleave, et al.
Blood|June 5, 2014
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomesEdgardo R Parrilla Castellar, Elaine S Jaffe, Jonathan W Said, et al.
Nature Genetics|August 20, 2025
Temporal genomic dynamics shape clinical trajectory in multiple myelomaFrancesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
Pageof 38

Showing results (311-320 of 371) with videos related to

Sort By:
Pageof 38
Blood Cancer Journal|February 11, 2022
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphomaFushen Sha, Michelle Okwali, Anna Alperovich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2024
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated AnalysisEric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, et al.
The Journal of Clinical Investigation|September 8, 2020
Germ cell tumors and associated hematologic malignancies evolve from a common shared precursorJustin Taylor, Mark Ta Donoghue, Caleb Ho, et al.
Cancer Discovery|July 10, 2019
Altered Nuclear Export Signal Recognition as a Driver of OncogenesisJustin Taylor, Maria Sendino, Alexander N Gorelick, et al.
Nature Cancer|February 11, 2021
The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencingSara Parsa, Ana Ortega-Molina, Hsia-Yuan Ying, et al.
Cancer Discovery|January 10, 2020
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in LymphomaPatrizia Mondello, Saber Tadros, Matt Teater, et al.
The Lancet. Haematology|May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.
Science Translational Medicine|June 11, 2025
DeepHeme, a high-performance, generalizable deep ensemble for bone marrow morphometry and hematologic diagnosisShenghuan Sun, Zhanghan Yin, Jacob G Van Cleave, et al.
Blood|June 5, 2014
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomesEdgardo R Parrilla Castellar, Elaine S Jaffe, Jonathan W Said, et al.
Nature Genetics|August 20, 2025
Temporal genomic dynamics shape clinical trajectory in multiple myelomaFrancesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
Pageof 38